共 50 条
- [21] Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Lee, Su JinHam, Jun SooKim, Hee KyungByeon, SeonggyuLee, Seon YoungLee, Weon SupYoo, Jin SanSun, Jong MuLee, JeeyunPark, Se HoonPark, Joon OhAhn, Myung-JuLim, Ho YeongKang, Won KiPark, Young Suk
- [22] Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Jimeno, AntonioLoRusso, PatriciaStrother, Robert MatthewDiamond, Jennifer RobinsonPlato, LeahYounger, AnneMessersmith, Wells A.Kittaneh, MuaiadSawyer, DougAdriaens, LieveLiu, LimingKao, Richard J.DiCioccio, A. ThomasBrownstein, Carrie M.Lowy, IsraelTrail, PamelaChiorean, E. Gabriela
- [23] Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 study in patients with advanced solid malignanciesEJC SUPPLEMENTS, 2006, 4 (12): : 63 - 63Mom, C. H.Sleijfer, S.Gietema, J. A.Fox, N. L.Piganeau, C.Lo, L.Uges, D. R. A.Loos, W.de Vries, E. G. E.Verweij, J.
- [24] Phase 1/2 trial of FF-10502-01, a pyrimidine antimetabolite, in patients with advanced cholangiocarcinoma and solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Janku, FilipSen, ShirajPant, ShubhamBramwell, LindsaySubbiah, VivekWay, TraceyJavle, Milind M.Stone, CassiePrajapati, BhumikaHagiwara, ShinjiJohansen, MaryMadden, TimothyMaier, GarySubach, Ruth AnnSaeki, KazunoriSuzuki, TakeakiWages, David S.Wheeler, Catherine A.Falchook, Gerald Steven
- [25] A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRIJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Sikic, B. I.Wakelee, H. A.von Mehren, M.Lewis, N.Calvert, A. H.Plummer, E. R.Fox, N. L.Howard, T.Jones, S. F.Burris, H. A., III
- [26] Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumorsINVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 782 - 790Lee, Su JinLee, Seon YoungLee, Weon SupYoo, Jin SanSun, Jong-MuLee, JeeyunPark, Se HoonPark, Joon OhAhn, Myung-JuLim, Ho YeongKang, Won KiPark, Young Suk
- [27] Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumorsInvestigational New Drugs, 2017, 35 : 782 - 790Su Jin LeeSeon Young LeeWeon Sup LeeJin San YooJong-Mu SunJeeyun LeeSe Hoon ParkJoon Oh ParkMyung-Ju AhnHo Yeong LimWon Ki KangYoung Suk Park
- [28] A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Wagner, Andrew J.Banerji, UdaiMahipal, AmitSomaiah, NeetaHirsch, Heather AnneFancourt, CraigLevonas, AmyLam, RaymondMeister, AmyKemp, Ramon KarmelKnox, ClaytonRose, ShelonitdaHong, David S.
- [29] A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI.MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3454S - 3455SSikic, Branimir I.Wakelee, Heather A.Von Mehren, MargaretLewis, Nancy L.Plummer, E. RuthCalvert, A. HilaryFox, Norma LynnKumm, Elizabeth A.Jones, Suzanne F.Burris, Howard A.
- [30] Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Forster, M. D.Patnaik, A.Sandhu, S. K.Papadopoulos, K.Tromp, B. J.Messiou, C.Balkwill, F.Berns, B.De Bono, J. S.Tolcher, A. W.